-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 31, the official website of the World Health Organization (WHO) released the "WHO Expert Evaluation Meeting on the Treatment of New Coronary Pneumonia with Traditional Chinese Medicine", which clearly pointed out the effectiveness of traditional Chinese medicine in the treatment of new coronary pneumonia, and encouraged member states to consider absorbing traditional Chinese medicine
.
The WHO's affirmation of the anti-epidemic effect of traditional Chinese medicine will promote more and more traditional Chinese medicine to go abroad
.
.
The WHO's affirmation of the anti-epidemic effect of traditional Chinese medicine will promote more and more traditional Chinese medicine to go abroad
.
It is definitely a good thing for the whole Chinese medicine industry and the health and well-being of the global people that traditional Chinese medicine goes abroad and goes global
.
But we are more worried about whether the quality and quantity supply of Chinese herbal medicine raw materials can adapt to the "going overseas" trip of Chinese medicine?
.
But we are more worried about whether the quality and quantity supply of Chinese herbal medicine raw materials can adapt to the "going overseas" trip of Chinese medicine?
Figure 1: CCTV reports that WHO affirms the safety and effectiveness of traditional Chinese medicine in the treatment of new coronary pneumonia
.
(picture source network)
.
(picture source network)
1.
Epidemic development: The overall situation is still severe, and the number of new cases remains high
Epidemic development: The overall situation is still severe, and the number of new cases remains high
Figure 2: Global new cases of COVID-19 from January 2020 to April 2022 (Data source: WHO)
(Note: The data in April 2022 is still being counted, and it is currently the forecast value)
Global situation: From January to April 2022, the number of new cases of new coronary pneumonia per month in the world is significantly higher than the same period in 2020 and 2021
.
On the one hand, due to the surging number of infected groups, the medical systems of various countries are operating at a high load and the medical supply is insufficient; on the other hand, the rapid mutation of the new coronavirus strain and the strong transmission ability have led to an increasing risk of infection
.
.
On the one hand, due to the surging number of infected groups, the medical systems of various countries are operating at a high load and the medical supply is insufficient; on the other hand, the rapid mutation of the new coronavirus strain and the strong transmission ability have led to an increasing risk of infection
.
Figure 3: New domestic COVID-19 cases from January 2021 to April 2022 (Data source: National Health Commission official website)
(Note: The data in April 2022 is still being counted, and the current statistics are as of 2022.
4.
13)
4.
13)
Domestic situation: From March to April 2022, local epidemics occurred in many places in China.
The number of cases in Jilin, Shandong, Shanghai, Guangdong and other provinces and cities increased rapidly, and the number of newly infected cases exceeded 10,000 for two consecutive months
.
Due to the characteristics of the new coronavirus Omicron strain with strong infectivity, strong concealment, and relatively mild symptoms, it is difficult to detect, and eventually leads to the simultaneous occurrence of multiple outbreaks in multiple locations, provinces and cities
.
The number of cases in Jilin, Shandong, Shanghai, Guangdong and other provinces and cities increased rapidly, and the number of newly infected cases exceeded 10,000 for two consecutive months
.
Due to the characteristics of the new coronavirus Omicron strain with strong infectivity, strong concealment, and relatively mild symptoms, it is difficult to detect, and eventually leads to the simultaneous occurrence of multiple outbreaks in multiple locations, provinces and cities
.
Second, the diagnosis and treatment plan revision: the content of traditional Chinese medicine is further enriched
On March 15, the National Health Commission and the State Administration of Traditional Chinese Medicine issued the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Ninth Edition)" (hereinafter referred to as the ninth edition of the diagnosis and treatment plan)
.
Compared with the previous version, this version of the diagnosis and treatment plan has added Chinese patent medicine, acupuncture and traditional Chinese medicine treatment for children; Huoxiang Zhengqi Capsules, Jinhua Qinggan Granules, Lianhua Qingwen Capsules (granules), etc.
are also recommended Medication; new dosage forms such as traditional Chinese medicine granules have been added to improve the convenience and adaptability of taking medicine
.
.
Compared with the previous version, this version of the diagnosis and treatment plan has added Chinese patent medicine, acupuncture and traditional Chinese medicine treatment for children; Huoxiang Zhengqi Capsules, Jinhua Qinggan Granules, Lianhua Qingwen Capsules (granules), etc.
are also recommended Medication; new dosage forms such as traditional Chinese medicine granules have been added to improve the convenience and adaptability of taking medicine
.
A total of 15 types of proprietary Chinese medicines are included in the ninth edition of the diagnosis and treatment plan.
The list and formulation are as follows:
The list and formulation are as follows:
Table 1: Chinese patent medicines and prescriptions included in the ninth edition of the diagnosis and treatment plan (Data source: State Administration of Traditional Chinese Medicine)
3.
Changes in the raw material market: the proportion of rising varieties is too high, and the cost of finished medicines is rising
Changes in the raw material market: the proportion of rising varieties is too high, and the cost of finished medicines is rising
Figure 4: The market price of Chinese patent medicine raw materials in the ninth edition of the diagnosis and treatment plan rose and fell year-on-year in April
The Chinese patent medicines and formula granules included in the ninth edition of the diagnosis and treatment plan involve a total of 67 kinds of raw materials of traditional Chinese medicinal materials, of which 43 kinds are rising, accounting for 64.
18%; 8 kinds are flat, accounting for 11.
94%, and 16 kinds are falling, accounting for 23.
88%
.
18%; 8 kinds are flat, accounting for 11.
94%, and 16 kinds are falling, accounting for 23.
88%
.
Table 2: Changes in 67 Chinese herbal medicines involved in the ninth edition of the diagnosis and treatment plan
4.
Raw material supply: more than half of the varieties have short growth cycles, and new production will surge in the future
Raw material supply: more than half of the varieties have short growth cycles, and new production will surge in the future
Figure 5: The ninth edition of the diagnosis and treatment protocol involves the growth cycle of raw materials
Among the 67 kinds of Chinese medicinal materials involved in the ninth edition of the diagnosis and treatment plan, 31 have a growth cycle of 1 year, accounting for 46.
27%; 11 have a growth cycle of 2 years, accounting for 16.
42%; and 3 years have a growth cycle.
15 species, accounting for 22.
39%; 6 species with a growth cycle of 4 years, accounting for 8.
96%; 2 species with a growth cycle of 5 years, accounting for 2.
99%; 1 species with a growth cycle of 6 years and 7 years , accounting for 1.
49% and 1.
49% respectively
.
27%; 11 have a growth cycle of 2 years, accounting for 16.
42%; and 3 years have a growth cycle.
15 species, accounting for 22.
39%; 6 species with a growth cycle of 4 years, accounting for 8.
96%; 2 species with a growth cycle of 5 years, accounting for 2.
99%; 1 species with a growth cycle of 6 years and 7 years , accounting for 1.
49% and 1.
49% respectively
.
Table 3: Classification of the growth cycle of 67 traditional Chinese medicinal materials involved in the ninth edition of the diagnosis and treatment plan
Varieties with a growth cycle of 1-2 years are less difficult to plant, easy to recover, and susceptible to changes in market conditions
.
.
The planting difficulty of varieties with a growth cycle of 3-4 years has increased, and production cannot be quickly recovered in the short term.
Changes in market conditions can easily stimulate production in production areas, resulting in continuous increases in future output
.
Changes in market conditions can easily stimulate production in production areas, resulting in continuous increases in future output
.
The planting cycle of varieties with a growth cycle of 5-7 years is too long, the difficulty of planting and management is significantly increased, and the production is not easy to resume
.
.
However, varieties such as Forsythia, Honeysuckle, Potbellied Bark, Caoguo, Citrus aurantium, etc.
, have the characteristics of one-time planting and many years of harvesting, and the market conditions will change with the changes in the output of the year
.
, have the characteristics of one-time planting and many years of harvesting, and the market conditions will change with the changes in the output of the year
.
5.
Overall evaluation: The supply of domestic medicinal materials is sufficient, and it is difficult to guarantee wild resources
Overall evaluation: The supply of domestic medicinal materials is sufficient, and it is difficult to guarantee wild resources
1.
The overall demand for anti-epidemic Chinese medicinal materials maintains growth With the approval of the WHO and more countries for the prevention and treatment of new coronary pneumonia by traditional Chinese medicine , the demand for anti- epidemic Chinese patent medicines and traditional Chinese medicine raw materials will also rise steadily
.
Especially recently, as the number of new coronavirus infections continues to increase, the supply of raw materials for anti-epidemic Chinese medicinal materials may be tight, and the market is running at a high level
.
The overall demand for anti-epidemic Chinese medicinal materials maintains growth With the approval of the WHO and more countries for the prevention and treatment of new coronary pneumonia by traditional Chinese medicine , the demand for anti- epidemic Chinese patent medicines and traditional Chinese medicine raw materials will also rise steadily
.
Especially recently, as the number of new coronavirus infections continues to increase, the supply of raw materials for anti-epidemic Chinese medicinal materials may be tight, and the market is running at a high level
.
2.
The overall production of domestic medicinal materials has expanded, and the supply is relatively sufficient.
According to the assessment of our center, due to the high overall price of Chinese medicinal materials in 2020-2021, the production will be stimulated, especially many high-priced varieties such as Poria, Angelica, Patchouli, Tulip, etc.
The rapid expansion of the production of varieties and the formation of the fundamentals of output exceeding sales are sufficient to ensure the growth of global demand for Chinese medicinal materials in anti-epidemic
.
The overall production of domestic medicinal materials has expanded, and the supply is relatively sufficient.
According to the assessment of our center, due to the high overall price of Chinese medicinal materials in 2020-2021, the production will be stimulated, especially many high-priced varieties such as Poria, Angelica, Patchouli, Tulip, etc.
The rapid expansion of the production of varieties and the formation of the fundamentals of output exceeding sales are sufficient to ensure the growth of global demand for Chinese medicinal materials in anti-epidemic
.
3.
It is difficult to guarantee wild and semi-wild resources, and the chain may be broken in the short term, especially the popular Chinese patent medicines such as Lianhua Qingwen Capsule, Qingfei Paidu Decoction, Pien Tze Huang and Angong Niuhuang Pills.
The source of raw materials, such as forsythia, rhodiola, natural bezoar, natural musk, etc.
, may be in short supply or even broken in the short term.
Relevant enterprises should pay close attention and strengthen strategic reserves
.
(Unless otherwise stated in the text, the data are all from the big data of the pharmaceutical industry in Tiandi Yuntu)
It is difficult to guarantee wild and semi-wild resources, and the chain may be broken in the short term, especially the popular Chinese patent medicines such as Lianhua Qingwen Capsule, Qingfei Paidu Decoction, Pien Tze Huang and Angong Niuhuang Pills.
The source of raw materials, such as forsythia, rhodiola, natural bezoar, natural musk, etc.
, may be in short supply or even broken in the short term.
Relevant enterprises should pay close attention and strengthen strategic reserves
.
(Unless otherwise stated in the text, the data are all from the big data of the pharmaceutical industry in Tiandi Yuntu)
On March 31, the official website of the World Health Organization (WHO) released the "WHO Expert Evaluation Meeting on the Treatment of New Coronary Pneumonia with Traditional Chinese Medicine", which clearly pointed out the effectiveness of traditional Chinese medicine in the treatment of new coronary pneumonia, and encouraged member states to consider absorbing traditional Chinese medicine
.
The WHO's affirmation of the anti-epidemic effect of traditional Chinese medicine will promote more and more traditional Chinese medicine to go abroad
.
.
The WHO's affirmation of the anti-epidemic effect of traditional Chinese medicine will promote more and more traditional Chinese medicine to go abroad
.
It is definitely a good thing for the whole Chinese medicine industry and the health and well-being of the global people that traditional Chinese medicine goes abroad and goes global
.
But we are more worried about whether the quality and quantity supply of Chinese herbal medicine raw materials can adapt to the "going overseas" trip of Chinese medicine?
.
But we are more worried about whether the quality and quantity supply of Chinese herbal medicine raw materials can adapt to the "going overseas" trip of Chinese medicine?
Figure 1: CCTV reports that WHO affirms the safety and effectiveness of traditional Chinese medicine in the treatment of new coronary pneumonia
.
(picture source network)
.
(picture source network)
1.
Epidemic development: The overall situation is still severe, and the number of new cases remains high
Epidemic development: The overall situation is still severe, and the number of new cases remains high
Figure 2: Global new cases of COVID-19 from January 2020 to April 2022 (Data source: WHO)
(Note: The data in April 2022 is still being counted, and it is currently the forecast value)
Global situation: From January to April 2022, the number of new cases of new coronary pneumonia per month in the world is significantly higher than the same period in 2020 and 2021
.
On the one hand, due to the surging number of infected groups, the medical systems of various countries are operating at a high load and the medical supply is insufficient; on the other hand, the rapid mutation of the new coronavirus strain and the strong transmission ability have led to an increasing risk of infection
.
.
On the one hand, due to the surging number of infected groups, the medical systems of various countries are operating at a high load and the medical supply is insufficient; on the other hand, the rapid mutation of the new coronavirus strain and the strong transmission ability have led to an increasing risk of infection
.
Figure 3: New domestic COVID-19 cases from January 2021 to April 2022 (Data source: National Health Commission official website)
(Note: The data in April 2022 is still being counted, and the current statistics are as of 2022.
4.
13)
4.
13)
Domestic situation: From March to April 2022, local epidemics occurred in many places in China.
The number of cases in Jilin, Shandong, Shanghai, Guangdong and other provinces and cities increased rapidly, and the number of newly infected cases exceeded 10,000 for two consecutive months
.
Due to the characteristics of the new coronavirus Omicron strain with strong infectivity, strong concealment, and relatively mild symptoms, it is difficult to detect, and eventually leads to the simultaneous occurrence of multiple outbreaks in multiple locations, provinces and cities
.
The number of cases in Jilin, Shandong, Shanghai, Guangdong and other provinces and cities increased rapidly, and the number of newly infected cases exceeded 10,000 for two consecutive months
.
Due to the characteristics of the new coronavirus Omicron strain with strong infectivity, strong concealment, and relatively mild symptoms, it is difficult to detect, and eventually leads to the simultaneous occurrence of multiple outbreaks in multiple locations, provinces and cities
.
Second, the diagnosis and treatment plan revision: the content of traditional Chinese medicine is further enriched
On March 15, the National Health Commission and the State Administration of Traditional Chinese Medicine issued the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Ninth Edition)" (hereinafter referred to as the ninth edition of the diagnosis and treatment plan)
.
Compared with the previous version, this version of the diagnosis and treatment plan has added Chinese patent medicine, acupuncture and traditional Chinese medicine treatment for children; Huoxiang Zhengqi Capsules, Jinhua Qinggan Granules, Lianhua Qingwen Capsules (granules), etc.
are also recommended Medication; new dosage forms such as traditional Chinese medicine granules have been added to improve the convenience and adaptability of taking medicine
.
.
Compared with the previous version, this version of the diagnosis and treatment plan has added Chinese patent medicine, acupuncture and traditional Chinese medicine treatment for children; Huoxiang Zhengqi Capsules, Jinhua Qinggan Granules, Lianhua Qingwen Capsules (granules), etc.
are also recommended Medication; new dosage forms such as traditional Chinese medicine granules have been added to improve the convenience and adaptability of taking medicine
.
A total of 15 types of proprietary Chinese medicines are included in the ninth edition of the diagnosis and treatment plan.
The list and formulation are as follows:
The list and formulation are as follows:
Table 1: Chinese patent medicines and prescriptions included in the ninth edition of the diagnosis and treatment plan (Data source: State Administration of Traditional Chinese Medicine)
3.
Changes in the raw material market: the proportion of rising varieties is too high, and the cost of finished medicines is rising
Changes in the raw material market: the proportion of rising varieties is too high, and the cost of finished medicines is rising
Figure 4: The market price of Chinese patent medicine raw materials in the ninth edition of the diagnosis and treatment plan rose and fell year-on-year in April
The Chinese patent medicines and formula granules included in the ninth edition of the diagnosis and treatment plan involve a total of 67 kinds of raw materials of traditional Chinese medicinal materials, of which 43 kinds are rising, accounting for 64.
18%; 8 kinds are flat, accounting for 11.
94%, and 16 kinds are falling, accounting for 23.
88%
.
18%; 8 kinds are flat, accounting for 11.
94%, and 16 kinds are falling, accounting for 23.
88%
.
Table 2: Changes in 67 Chinese herbal medicines involved in the ninth edition of the diagnosis and treatment plan
4.
Raw material supply: more than half of the varieties have short growth cycles, and new production will surge in the future
Raw material supply: more than half of the varieties have short growth cycles, and new production will surge in the future
Figure 5: The ninth edition of the diagnosis and treatment protocol involves the growth cycle of raw materials
Among the 67 kinds of Chinese medicinal materials involved in the ninth edition of the diagnosis and treatment plan, 31 have a growth cycle of 1 year, accounting for 46.
27%; 11 have a growth cycle of 2 years, accounting for 16.
42%; and 3 years have a growth cycle.
15 species, accounting for 22.
39%; 6 species with a growth cycle of 4 years, accounting for 8.
96%; 2 species with a growth cycle of 5 years, accounting for 2.
99%; 1 species with a growth cycle of 6 years and 7 years , accounting for 1.
49% and 1.
49% respectively
.
27%; 11 have a growth cycle of 2 years, accounting for 16.
42%; and 3 years have a growth cycle.
15 species, accounting for 22.
39%; 6 species with a growth cycle of 4 years, accounting for 8.
96%; 2 species with a growth cycle of 5 years, accounting for 2.
99%; 1 species with a growth cycle of 6 years and 7 years , accounting for 1.
49% and 1.
49% respectively
.
Table 3: Classification of the growth cycle of 67 traditional Chinese medicinal materials involved in the ninth edition of the diagnosis and treatment plan
Varieties with a growth cycle of 1-2 years are less difficult to plant, easy to recover, and susceptible to changes in market conditions
.
.
The planting difficulty of varieties with a growth cycle of 3-4 years has increased, and production cannot be quickly recovered in the short term.
Changes in market conditions can easily stimulate production in production areas, resulting in continuous increases in future output
.
Changes in market conditions can easily stimulate production in production areas, resulting in continuous increases in future output
.
The planting cycle of varieties with a growth cycle of 5-7 years is too long, the difficulty of planting and management is significantly increased, and the production is not easy to resume
.
.
However, varieties such as Forsythia, Honeysuckle, Potbellied Bark, Caoguo, Citrus aurantium, etc.
, have the characteristics of one-time planting and many years of harvesting, and the market conditions will change with the changes in the output of the year
.
, have the characteristics of one-time planting and many years of harvesting, and the market conditions will change with the changes in the output of the year
.
5.
Overall evaluation: The supply of domestic medicinal materials is sufficient, and it is difficult to guarantee wild resources
Overall evaluation: The supply of domestic medicinal materials is sufficient, and it is difficult to guarantee wild resources
1.
The overall demand for anti-epidemic Chinese medicinal materials maintains growth With the approval of the WHO and more countries for the prevention and treatment of new coronary pneumonia by traditional Chinese medicine , the demand for anti- epidemic Chinese patent medicines and traditional Chinese medicine raw materials will also rise steadily
.
Especially recently, as the number of new coronavirus infections continues to increase, the supply of raw materials for anti-epidemic Chinese medicinal materials may be tight, and the market is running at a high level
.
The overall demand for anti-epidemic Chinese medicinal materials maintains growth With the approval of the WHO and more countries for the prevention and treatment of new coronary pneumonia by traditional Chinese medicine , the demand for anti- epidemic Chinese patent medicines and traditional Chinese medicine raw materials will also rise steadily
.
Especially recently, as the number of new coronavirus infections continues to increase, the supply of raw materials for anti-epidemic Chinese medicinal materials may be tight, and the market is running at a high level
.
2.
The overall production of domestic medicinal materials has expanded, and the supply is relatively sufficient.
According to the assessment of our center, due to the high overall price of Chinese medicinal materials in 2020-2021, the production will be stimulated, especially many high-priced varieties such as Poria, Angelica, Patchouli, Tulip, etc.
The rapid expansion of the production of varieties and the formation of the fundamentals of output exceeding sales are sufficient to ensure the growth of global demand for Chinese medicinal materials in anti-epidemic
.
The overall production of domestic medicinal materials has expanded, and the supply is relatively sufficient.
According to the assessment of our center, due to the high overall price of Chinese medicinal materials in 2020-2021, the production will be stimulated, especially many high-priced varieties such as Poria, Angelica, Patchouli, Tulip, etc.
The rapid expansion of the production of varieties and the formation of the fundamentals of output exceeding sales are sufficient to ensure the growth of global demand for Chinese medicinal materials in anti-epidemic
.
3.
It is difficult to guarantee wild and semi-wild resources, and the chain may be broken in the short term, especially the popular Chinese patent medicines such as Lianhua Qingwen Capsule, Qingfei Paidu Decoction, Pien Tze Huang and Angong Niuhuang Pills.
The source of raw materials, such as forsythia, rhodiola, natural bezoar, natural musk, etc.
, may be in short supply or even broken in the short term.
Relevant enterprises should pay close attention and strengthen strategic reserves
.
(Unless otherwise stated in the text, the data are all from the big data of the pharmaceutical industry in Tiandi Yuntu)
It is difficult to guarantee wild and semi-wild resources, and the chain may be broken in the short term, especially the popular Chinese patent medicines such as Lianhua Qingwen Capsule, Qingfei Paidu Decoction, Pien Tze Huang and Angong Niuhuang Pills.
The source of raw materials, such as forsythia, rhodiola, natural bezoar, natural musk, etc.
, may be in short supply or even broken in the short term.
Relevant enterprises should pay close attention and strengthen strategic reserves
.
(Unless otherwise stated in the text, the data are all from the big data of the pharmaceutical industry in Tiandi Yuntu)
On March 31, the official website of the World Health Organization (WHO) released the "WHO Expert Evaluation Meeting on the Treatment of New Coronary Pneumonia with Traditional Chinese Medicine", which clearly pointed out the effectiveness of traditional Chinese medicine in the treatment of new coronary pneumonia, and encouraged member states to consider absorbing traditional Chinese medicine
.
The WHO's affirmation of the anti-epidemic effect of traditional Chinese medicine will promote more and more traditional Chinese medicine to go abroad
.
.
The WHO's affirmation of the anti-epidemic effect of traditional Chinese medicine will promote more and more traditional Chinese medicine to go abroad
.
It is definitely a good thing for the whole Chinese medicine industry and the health and well-being of the global people that traditional Chinese medicine goes abroad and goes global
.
But we are more worried about whether the quality and quantity supply of Chinese herbal medicine raw materials can adapt to the "going overseas" trip of Chinese medicine?
Traditional Chinese Medicine Traditional Chinese Medicine Traditional ChineseMedicine.
But we are more worried about whether the quality and quantity supply of Chinese herbal medicine raw materials can adapt to the "going overseas" trip of Chinese medicine?
Figure 1: CCTV reports that WHO affirms the safety and effectiveness of traditional Chinese medicine in the treatment of new coronary pneumonia
.
(picture source network)
.
(picture source network)
1.
Epidemic development: The overall situation is still severe, and the number of new cases remains high
1. Epidemic development: The overall situation is still severe, and the number of new cases remains high
Epidemic development: The overall situation is still severe, and the number of new cases remains high
Figure 2: Global new cases of COVID-19 from January 2020 to April 2022 (Data source: WHO)
(Note: The data in April 2022 is still being counted, and it is currently the forecast value)
Global situation: From January to April 2022, the number of new cases of new coronary pneumonia per month in the world is significantly higher than the same period in 2020 and 2021
.
On the one hand, due to the surging number of infected groups, the medical systems of various countries are operating at a high load and the medical supply is insufficient; on the other hand, the rapid mutation of the new coronavirus strain and the strong transmission ability have led to an increasing risk of infection
.
.
On the one hand, due to the surging number of infected groups, the medical systems of various countries are operating at a high load and the medical supply is insufficient; on the other hand, the rapid mutation of the new coronavirus strain and the strong transmission ability have led to an increasing risk of infection
.
Figure 3: New domestic COVID-19 cases from January 2021 to April 2022 (Data source: National Health Commission official website)
(Note: The data in April 2022 is still being counted, and the current statistics are as of 2022.
4.
13)
4.
13)
Domestic situation: From March to April 2022, local epidemics occurred in many places in China.
The number of cases in Jilin, Shandong, Shanghai, Guangdong and other provinces and cities increased rapidly, and the number of newly infected cases exceeded 10,000 for two consecutive months
.
Due to the characteristics of the new coronavirus Omicron strain with strong infectivity, strong concealment, and relatively mild symptoms, it is difficult to detect, and eventually leads to the simultaneous occurrence of multiple outbreaks in multiple locations, provinces and cities
.
The number of cases in Jilin, Shandong, Shanghai, Guangdong and other provinces and cities increased rapidly, and the number of newly infected cases exceeded 10,000 for two consecutive months
.
Due to the characteristics of the new coronavirus Omicron strain with strong infectivity, strong concealment, and relatively mild symptoms, it is difficult to detect, and eventually leads to the simultaneous occurrence of multiple outbreaks in multiple locations, provinces and cities
.
Second, the diagnosis and treatment plan revision: the content of traditional Chinese medicine is further enriched
Second, the diagnosis and treatment plan revision: the content of traditional Chinese medicine is further enriched On March 15, the National Health Commission and the State Administration of Traditional Chinese Medicine issued the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Ninth Edition)" (hereinafter referred to as the ninth edition of the diagnosis and treatment plan)
.
Compared with the previous version, this version of the diagnosis and treatment plan has added Chinese patent medicine, acupuncture and traditional Chinese medicine treatment for children; Huoxiang Zhengqi Capsules, Jinhua Qinggan Granules, Lianhua Qingwen Capsules (granules), etc.
are also recommended Medication; new dosage forms such as traditional Chinese medicine granules have been added to improve the convenience and adaptability of taking medicine
.
.
Compared with the previous version, this version of the diagnosis and treatment plan has added Chinese patent medicine, acupuncture and traditional Chinese medicine treatment for children; Huoxiang Zhengqi Capsules, Jinhua Qinggan Granules, Lianhua Qingwen Capsules (granules), etc.
are also recommended Medication; new dosage forms such as traditional Chinese medicine granules have been added to improve the convenience and adaptability of taking medicine
.
A total of 15 types of proprietary Chinese medicines are included in the ninth edition of the diagnosis and treatment plan.
The list and formulation are as follows:
The list and formulation are as follows:
Table 1: Chinese patent medicines and prescriptions included in the ninth edition of the diagnosis and treatment plan (Data source: State Administration of Traditional Chinese Medicine)
3.
Changes in the raw material market: the proportion of rising varieties is too high, and the cost of finished medicines is rising
3. Changes in the raw material market: the proportion of rising varieties is too high, and the cost of finished medicines is rising
Changes in the raw material market: the proportion of rising varieties is too high, and the cost of finished medicines is rising
Figure 4: The market price of Chinese patent medicine raw materials in the ninth edition of the diagnosis and treatment plan rose and fell year-on-year in April
The Chinese patent medicines and formula granules included in the ninth edition of the diagnosis and treatment plan involve a total of 67 kinds of raw materials of traditional Chinese medicinal materials, of which 43 kinds are rising, accounting for 64.
18%; 8 kinds are flat, accounting for 11.
94%, and 16 kinds are falling, accounting for 23.
88%
.
18%; 8 kinds are flat, accounting for 11.
94%, and 16 kinds are falling, accounting for 23.
88%
.
Table 2: Changes in 67 Chinese herbal medicines involved in the ninth edition of the diagnosis and treatment plan
4.
Raw material supply: more than half of the varieties have short growth cycles, and new production will surge in the future
4. Raw material supply: more than half of the varieties have short growth cycles, and new production will surge in the future
Raw material supply: more than half of the varieties have short growth cycles, and new production will surge in the future
Figure 5: The ninth edition of the diagnosis and treatment protocol involves the growth cycle of raw materials
Among the 67 kinds of Chinese medicinal materials involved in the ninth edition of the diagnosis and treatment plan, 31 have a growth cycle of 1 year, accounting for 46.
27%; 11 have a growth cycle of 2 years, accounting for 16.
42%; and 3 years have a growth cycle.
15 species, accounting for 22.
39%; 6 species with a growth cycle of 4 years, accounting for 8.
96%; 2 species with a growth cycle of 5 years, accounting for 2.
99%; 1 species with a growth cycle of 6 years and 7 years , accounting for 1.
49% and 1.
49% respectively
.
27%; 11 have a growth cycle of 2 years, accounting for 16.
42%; and 3 years have a growth cycle.
15 species, accounting for 22.
39%; 6 species with a growth cycle of 4 years, accounting for 8.
96%; 2 species with a growth cycle of 5 years, accounting for 2.
99%; 1 species with a growth cycle of 6 years and 7 years , accounting for 1.
49% and 1.
49% respectively
.
Table 3: Classification of the growth cycle of 67 traditional Chinese medicinal materials involved in the ninth edition of the diagnosis and treatment plan
Varieties with a growth cycle of 1-2 years are less difficult to plant, easy to recover, and susceptible to changes in market conditions
.
.
The planting difficulty of varieties with a growth cycle of 3-4 years has increased, and production cannot be quickly recovered in the short term.
Changes in market conditions can easily stimulate production in production areas, resulting in continuous increases in future output
.
Changes in market conditions can easily stimulate production in production areas, resulting in continuous increases in future output
.
The planting cycle of varieties with a growth cycle of 5-7 years is too long, the difficulty of planting and management is significantly increased, and the production is not easy to resume
.
.
However, varieties such as Forsythia, Honeysuckle, Potbellied Bark, Caoguo, Citrus aurantium, etc.
, have the characteristics of one-time planting and many years of harvesting, and the market conditions will change with the changes in the output of the year
.
, have the characteristics of one-time planting and many years of harvesting, and the market conditions will change with the changes in the output of the year
.
5.
Overall evaluation: The supply of domestic medicinal materials is sufficient, and it is difficult to guarantee wild resources
5. Overall evaluation: The supply of domestic medicinal materials is sufficient, and it is difficult to guarantee wild resources
Overall evaluation: The supply of domestic medicinal materials is sufficient, and it is difficult to guarantee wild resources
1.
The overall demand for anti-epidemic Chinese medicinal materials maintains growth With the approval of the WHO and more countries for the prevention and treatment of new coronary pneumonia by traditional Chinese medicine , the demand for anti- epidemic Chinese patent medicines and traditional Chinese medicine raw materials will also rise steadily
.
Especially recently, as the number of new coronavirus infections continues to increase, the supply of raw materials for anti-epidemic Chinese medicinal materials may be tight, and the market is running at a high level
.
medicine medicine medicineThe overall demand for anti-epidemic Chinese medicinal materials maintains growth With the approval of the WHO and more countries for the prevention and treatment of new coronary pneumonia by traditional Chinese medicine , the demand for anti- epidemic Chinese patent medicines and traditional Chinese medicine raw materials will also rise steadily
.
Especially recently, as the number of new coronavirus infections continues to increase, the supply of raw materials for anti-epidemic Chinese medicinal materials may be tight, and the market is running at a high level
.
2.
The overall production of domestic medicinal materials has expanded, and the supply is relatively sufficient.
According to the assessment of our center, due to the high overall price of Chinese medicinal materials in 2020-2021, the production will be stimulated, especially many high-priced varieties such as Poria, Angelica, Patchouli, Tulip, etc.
The rapid expansion of the production of varieties and the formation of the fundamentals of output exceeding sales are sufficient to ensure the growth of global demand for Chinese medicinal materials in anti-epidemic
.
The overall production of domestic medicinal materials has expanded, and the supply is relatively sufficient.
According to the assessment of our center, due to the high overall price of Chinese medicinal materials in 2020-2021, the production will be stimulated, especially many high-priced varieties such as Poria, Angelica, Patchouli, Tulip, etc.
The rapid expansion of the production of varieties and the formation of the fundamentals of output exceeding sales are sufficient to ensure the growth of global demand for Chinese medicinal materials in anti-epidemic
.
3.
It is difficult to guarantee wild and semi-wild resources, and the chain may be broken in the short term, especially the popular Chinese patent medicines such as Lianhua Qingwen Capsule, Qingfei Paidu Decoction, Pien Tze Huang and Angong Niuhuang Pills.
The source of raw materials, such as forsythia, rhodiola, natural bezoar, natural musk, etc.
, may be in short supply or even broken in the short term.
Relevant enterprises should pay close attention and strengthen strategic reserves
.
(Unless otherwise stated in the text, the data are all from the big data of the pharmaceutical industry in Tiandi Yuntu)
enterprise enterprise enterprise It is difficult to guarantee wild and semi-wild resources, and the chain may be broken in the short term, especially the popular Chinese patent medicines such as Lianhua Qingwen Capsule, Qingfei Paidu Decoction, Pien Tze Huang and Angong Niuhuang Pills.
The source of raw materials, such as forsythia, rhodiola, natural bezoar, natural musk, etc.
, may be in short supply or even broken in the short term.
Relevant enterprises should pay close attention and strengthen strategic reserves
.
(Unless otherwise stated in the text, the data are all from the big data of the pharmaceutical industry in Tiandi Yuntu)
